Wells Fargo analyst Derek Archila upgraded Apellis Pharmaceuticals to Overweight from Equal Weight with a price target of $64, up from $34. The analyst likes the stock’s risk/reward into the Q3 earnings report and thinks Syfovre is on track to beat consensus estimates. In addition, J-code starting in October and stabilizing RV rates should accelerating utilization, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals put volume heavy and directionally bearish
- Apellis price target raised to $43 from $40 at BofA
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- Apellis price target raised to $54 from $45 at Citi